Oppenheimer Reiterates Outperform on CRISPR Therapeutics, Maintains $102 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Jay Olson has reiterated an 'Outperform' rating on CRISPR Therapeutics (NASDAQ:CRSP) and maintained a price target of $102.
August 10, 2023 | 3:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer's reiteration of an 'Outperform' rating and a $102 price target for CRISPR Therapeutics could potentially boost investor confidence.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. In this case, Oppenheimer's reiteration of an 'Outperform' rating and a $102 price target for CRISPR Therapeutics (CRSP) could potentially boost investor confidence and positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100